BioSpace News Archive

IRLAB Therapeutics AB announced an invitation to its industry symposium at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders on Friday, March 31, 2023.

XNK Therapeutics AB announced its extensive participation at the 8th Annual Innate Killer Summit in La Jolla, San Diego, CA, March 28-30.

Infinity Laboratories is proud to announce the hiring of Hank Nowak as our new Senior Vice President of Commercial Operations.

Flare Therapeutics Inc. announced a $123 million Series B financing co-led by GordonMD® Global Investments LP and Pfizer Ventures, with participation from existing investors Boxer Capital, Casdin Capital, Eventide Asset Management, Invus Financial Advisors, Nextech Invest and Third Rock Ventures and new investors Agent Capital, Eli Lilly and Company, Memorial Sloan Kettering Cancer Center, Novartis, Pavilion Capital and ShangBay Capital.

Oculis Holding AG announces that it will ring the Nasdaq opening bell to celebrate its public listing on the Nasdaq Stock Market earlier this month.

Plus Therapeutics, Inc. today announced treatment of the first patient in Cohort 3 of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium ( 186 Re) obisbemeda for the treatment of leptomeningeal metastases (LM) from solid tumors.

89bio, Inc. today announced positive topline data from the Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with nonalcoholic steatohepatitis (NASH).

Axon Therapies today announced positive 6-month results from a roll-in cohort for their feasibility IDE trial, REBALANCE-HF.

Dewpoint Therapeutics today announced a research and development partnership with Novo Nordisk to identify drug candidates using Dewpoint’s discovery platform related to biomolecular condensates to treat insulin resistance and diabetic complications.

Invitae (NYSE: NVTA), a leading medical genetics company, and Deerfield Management Company today announced a partnership to advance genetics-based drug discovery and development in rare disease.